GDF-15 as a target and biomarker for diabetes and cardiovascular diseases: A translational prospective

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Adela, Ramu ^a   Banerjee, Sanjay K ^a  

^a TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; NITRIC OXIDE; BIOLOGICAL MARKER; GDF15 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CLINICAL STUDY; COMMUNITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY DISEASE; MOLECULAR INTERACTION; NONHUMAN; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN SECRETION; TRANSLATIONAL RESEARCH; ADIPOCYTE; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; CLINICAL DECISION SUPPORT SYSTEM; CYTOLOGY; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASES; METABOLISM; PHYSIOLOGY; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION;

ADIPOCYTES; ANIMALS; ATHEROSCLEROSIS; BIOMARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DECISION SUPPORT SYSTEMS, CLINICAL; DIABETES MELLITUS; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASES; NITRIC OXIDE; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84939172537     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/490842     Document Type: Article

References (120)

1. International Diabetes Federation Diabetes Atlas, 6th edition, 2013.
2. S. M. Grundy, B. Howard, S. Smith Jr., R. Eckel, R. Redberg, and R. O. Bonow, "Diabetes and cardiovascular disease-executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association," Circulation, vol. 105, no. 18, pp. 2231-2239, 2002.
3. J. Kaur, "A comprehensive review on metabolic syndrome," Cardiology Research and Practice, vol. 2014, Article ID 943162, 21 pages, 2014.
4. W. I. Sivitz, "Lipotoxicity and glucotoxicity in type 2 diabetes. Effects on development and progression," Postgraduate Medicine, vol. 109, no. 4, pp. 55-64, 2001.
5. J. Li, L. Yang, W. Qin, G. Zhang, J. Yuan, and F. Wang, "Adaptive induction of growth differentiation factor 15 attenuates endothelial cell apoptosis in response to high glucose stimulus," PLoS ONE, vol. 8, no. 6, Article ID e65549, 2013.
6. M. Yokoyama-Kobayashi, M. Saeki, S. Sekine, and S. Kato, "Human cDNA encoding a novel TGF-β superfamily protein highly expressed in placenta," Journal of Biochemistry, vol. 122, no. 3, pp. 622-626, 1997.
7. T. Kempf, M. Eden, J. Strelau, et al., "The transforming growth factor-β superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury," Circulation Research, vol. 98, no. 3, pp. 351-360, 2006.
8. W. D. Fairlie, A. G. Moore, A. R. Bauskin, P. K. Russell, H. R. Zhang, and S. N. Breit, "MIC-1 is a novel TGF-β superfamily cytokine associated with macrophage activation," Journal of Leukocyte Biology, vol. 65, no. 1, pp. 2-5, 1999.
9. M. R. Bootcov, A. R. Bauskin, S. M. Valenzuela, et al., "MIC-1, a novelmacrophage inhibitory cytokine, is a divergentmember of the TGF-beta superfamily," Proceedings of theNational Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11514-11519, 1997.
10. D. A. Brown, C. Stephan, R. L. Ward, et al., "Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis," Clinical Cancer Research, vol. 12, no. 1, pp. 89-96, 2006.
11. A. Simm, N. Nass, B. Bartling, B. Hofmann, R.-E. Silber, and A. Navarrete Santos, "Potential biomarkers of ageing," Biological Chemistry, vol. 389, no. 3, pp. 257-265, 2008.
12. A. R. Bauskin, D. A. Brown, T. Kuffner, et al., "Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer," Cancer Research, vol. 66, no. 10, pp. 4983-4986, 2006.
13. F. E. Wiklund, A. M. Bennet, P. K. E. Magnusson, et al., "Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-causemortality," Aging Cell, vol. 9, no. 6, pp. 1057-1064, 2010.
14. B. Lindahl, "The story of growth differentiation factor 15: another piece of the puzzle," Clinical Chemistry, vol. 59, no. 11, pp. 1550-1552, 2013.
15. L. Wallentin, Z. Hijazi, U. Andersson, et al., "Growth differentiation factor-15, amarker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial," Circulation, vol. 130, no. 21, pp. 1847-1858, 2014.
16. J. B. Welsh, L. M. Sapinoso, A. I. Su, et al., "Analysis of gene expression identifies cand idate markers and pharmacological targets in prostate cancer," Cancer Research, vol. 61, no. 16, pp. 5974-5978, 2001.
17. P. Buckhaults, C. Rago, B. St. Croix, et al., "Secreted and cell surface genes expressed in benign and malignant colorectal tumors," Cancer Research, vol. 61, no. 19, pp. 6996-7001, 2001.
18. J. B. Welsh, L. M. Sapinoso, S. G. Kern, et al., "Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 6, pp. 3410-3415, 2003.
19. T. Liu, A. R. Bauskin, J. Zaunders, et al., "Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells," Cancer Research, vol. 63, no. 16, pp. 5034-5040, 2003.
20. D. A. Brown, R. L. Ward, P. Buckhaults, et al., "MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma," Clinical Cancer Research, vol. 9, no. 7, pp. 2642-2650, 2003.
21. M. Lajer, A. Jorsal, L. Tarnow, H.-H. Parving, and P. Rossing, "Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascularmortality aswell as deterioration of kidney function in type 1 diabetic patients with nephropathy," Diabetes Care, vol. 33, no. 7, pp. 1567-1572, 2010.
22. T. Kempf, A. Guba-Quint, J. Torgerson, et al., "Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial," European Journal of Endocrinology, vol. 167, no. 5, pp. 671-678, 2012.
23. G. Vila, M. Riedl, C. Anderwald, et al., "The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients," Clinical Chemistry, vol. 57, no. 2, pp. 309-316, 2011.
24. M. Carstensen, C. Herder, E. J. Brunner, et al., "Macrophage inhibitory cytokine-1 is increased in individuals before type diabetes diagnosis but is not an independent predictor of type 2 diabetes: the Whitehall II study," European Journal of Endocrinology, vol. 162, no. 5, pp. 913-917, 2010.
25. I. Dostalova, T. Roubicek, M. Bartlova, et al., "Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet," European Journal of Endocrinology, vol. 161, pp. 397-404, 2009.
26. M. Sugulle, R. Dechend, F. Herse, et al., "Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus," Hypertension, vol. 54, no. 1, pp. 106-112, 2009.
27. A. Dominguez-Rodriguez, P. Abreu-Gonzalez, and P. Avanzas, "Usefulness of growth differentiation factor-15 levels to predict diabetic cardiomyopathy in asymptomatic patients with type 2 diabetes mellitus,"The American Journal of Cardiology, vol. 114, no. 6, pp. 890-894, 2014.
28. H. Li, F. Gao, Y. Xue, and Y. Qian, "Value of plasma growth differentiation factor-15 in diagnosis and evaluation of type 2 diabetic nephropathy," Nan Fang Yi Ke Da Xue Xue Bao, vol. 34, no. 3, pp. 387-390, 2014.
29. S. Q. Khan, K. Ng, O. Dhillon, et al., "Growth differentiation factor-15 as a prognostic marker in patients with acutemyocardial infarction," European Heart Journal, vol. 30, no. 9, pp. 1057-1065, 2009.
30. M. P. Bonaca, D. A. Morrow, E. Braunwald, et al., "Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 1, pp. 203-210, 2011.
31. S. A. A. Bloch, J. Y. Lee, S. J. Wort, M. I. Polkey, P. R. Kemp, and M. J. D. Griffiths, "S73 circulating regulatorsof acutemuscle wasting in the critically ill: GDF-15 a potential novel driver of acutemusclewasting," Thorax, vol. 67, supplement 2, articleA37, 2012.
32. K. C. Wollert, T. Kempf, B. Lagerqvist, et al., "Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non-ST-elevation acute coronary syndrome," Circulation, vol. 116, no. 14, pp. 1540-1548, 2007.
33. A. Rohatgi, P. Patel, S. R. Das, et al., "Association of Growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multi ethnic population: observations fromthe Dallas Heart Study," Clinical Chemistry, vol. 58, no. 1, pp. 172-182, 2012.
34. J. E. Ho, S.-J. Hwang, K. C. Wollert, et al., "Biomarkers of cardiovascular stress and incident chronic kidney disease," Clinical Chemistry, vol. 59, no. 11, pp. 1613-1620, 2013.
35. S. Hanatani, Y. Izumiya, S. Takashio, et al., "Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts," Heart and Vessels, vol. 29, no. 2, pp. 231-237, 2014.
36. W. Dinh, R. Füth, M. Lankisch, et al., "Growth-differentiation factor-15: a novel biomarker in patients with diastolic dysfunction?" Arquivos Brasileiros de Cardiologia, vol. 97, no. 1, pp. 65-75, 2011.
37. D. W. Schopfer, I. A. Ku, M. Regan, and M. A. Whooley, "Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study)," American Heart Journal, vol. 167, no. 2, pp. 186-192, 2014.
38. H. Xue, Z. Fu, Y. Chen, et al., "The Association of Growth differentiation factor-15 with left ventricular hypertrophy in hypertensive patients," PLoS ONE, vol. 7, no. 10, Article ID e46534, 2012.
39. L. Wallentin, B. Zethelius, L. Berglund, et al., "GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men," PLoS ONE, vol. 8, no. 12, Article ID e78797, 2013.
40. I. S. Anand, T. Kempf, T. S. Rector, et al., "Serial measurement of growth-differentiation factor-15 in heart failure: Relation to disease severity and prognosis in the valsartan heart failure trial," Circulation, vol. 122, no. 14, pp. 1387-1395, 2010.
41. L. Y. Fan, Z. G. Jin, M. Zong, et al., "Growth differentiation factor 15, ischemiamodified albumin and pregnancy-associated plasma protein A in patients with coronary artery disease," Clinical Laboratory, vol. 60, no. 6, pp. 973-982, 2014.
42. A. Kahli, C. Guenancia, M. Zeller, et al., "Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass," PLoS ONE, vol. 9, no. 8, Article ID e105759, 2014.
43. H. Yilmaz, H. T. Çelik, O. M. Gurel, et al., "Increased serum levels of GDF-15 associated with mortality and subclinical atherosclerosis in patients onmaintenance hemodialysis," Herz, 2014.
44. J.-F. Lin, S. Wu, S.-Y. Hsu, et al., "Growth-differentiation factor-and major cardiac events," American Journal of the Medical Sciences, vol. 347, no. 4, pp. 305-311, 2014.
45. N. Schaub, T. Reichlin, R. Twerenbold, et al., "Growth differentiation factor-15 in the early diagnosis and risk stratification of patients with acute chest pain," Clinical Chemistry, vol. 58, no. 2, pp. 441-449, 2012.
46. J. Koopmann, P. Buckhaults, D. A. Brown, et al., "Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers," Clinical Cancer Research, vol. 10, no. 7, pp. 2386-2392, 2004.
47. M. Tan, Y. Wang, K. Guan, and Y. Sun, "PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGFbeta signaling pathway," Proceedings of the National Academy of Sciences of theUnited States of America, vol. 97, no. 1, pp. 109-114, 2000.
48. B. Bermúdez, S. López, Y. M. Pacheco, et al., "Influence of postprand ial triglyceride-rich lipoproteins on lipid mediated gene expression in smooth muscle cells of the human coronary artery," Cardiovascular Research, vol. 79, no. 2, pp. 294-303, 2008.
49. D. Schlittenhardt, A. Schober, J. Strelau, et al., "Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions," Cell and Tissue Research, vol. 318, no. 2, pp. 325-333, 2004.
50. Q. Ding, T. Mracek, P. Gonzalez-Muniesa, et al., "Identification of macrophage inhibitory cytokine-1 in adipose tissue and its secretion as an adipokine by human adipocytes," Endocrinology, vol. 150, no. 4, pp. 1688-1696, 2009.
51. N. Ferrari, U. Pfeffer, R. DellEva, C. Ambrosini, D. M. Noonan, and A. Albini, "The transforming growth factor-β family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl) retinamide," Clinical Cancer Research, vol. 11, no. 12, pp. 4610-4619, 2005.
52. A. R. Bauskin, D. A. Brown, S. Junankar, et al., "The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome," Cancer Research, vol. 65, no. 6, pp. 2330-2336, 2005.
53. J. Jurczyluk, D. Brown, and K. K. Stanley, "Polarised secretion of cytokines in primary human microvascular endothelial cells is not dependent on N-linked glycosylation," Cell Biology International, vol. 27, no. 12, pp. 997-1003, 2003.
54. T. Kempf, M. Eden, J. Strelau, et al., "The transforming growth factor-beta superfamily member growth-differentiation factor-β protects the heart from ischemia/reperfusion injury," Circulation Research, vol. 98, no. 3, pp. 351-360, 2006.
55. J. Wang, N. Xu, X. Feng, et al., "Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure," Circulation Research, vol. 97, no. 8, pp. 821-828, 2005.
56. S. I. Lok, B. Winkens, R. Goldschmeding, et al., "Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy decreases rapidly after left ventricular assist device support," European Journal of Heart Failure, vol. 14, no. 11, pp. 1249-1256, 2012.
57. J. Strelau, A. Sullivan, M. Bottner, et al., "Growth/differentiation factor-15/macrophage inhibitory cytokine-1 is a novel trophic factor for midbrain dopaminergic neurons in vivo," The Journal of Neuroscience, vol. 20, no. 23, pp. 8597-8603, 2000.
58. K. M. Flegal, B. I. Graubard, D. F. Williamson, and M. H. Gail, "Cause-specific excess deaths associated with underweight, overweight, and obesity," Journal of the American Medical Association, vol. 298, no. 17, pp. 2028-2037, 2007.
59. M. Shimano, N. Ouchi, and K. Walsh, "Cardiokines: recent progress in elucidating the cardiac secretome," Circulation, vol. 126, no. 21, pp. e327-e332, 2012.
60. L. Macia, V. W.-W. Tsai, A. D. Nguyen, et al., "Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets," PLoS ONE, vol. 7, no. 4, Article ID e34868, 2012.
61. K. Chrysovergis, X. Wang, J. Kosak, et al., "NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism," International Journal of Obesity, 2014.
62. I. Afanasev, "Signaling of reactive oxygen and nitrogen species in diabetes mellitus," OxidativeMedicine and Cellular Longevity, vol. 3, no. 6, pp. 361-373, 2010.
63. F. M. Ho, W. W. Lin, B. C. Chen, et al., "High glucose-induced apoptosis in human vascular endothelial cells is mediated through NF-kappaB and c-Jun NH2-terminal kinase pathway and prevented by PI3K/Akt/eNOS pathway," Cellular Signalling, vol. 18, no. 3, pp. 391-399, 2006.
64. J. A. Kelly, M. Scott Lucia, and J. R. Lambert, "p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms," Cancer Letters, vol. 277, no. 1, pp. 38-47, 2009.
65. K. C. Wollert and T. Kempf, "Growth differentiation factor 15 in heart failure: an update," Current Heart Failure Reports, vol. 9, no. 4, pp. 337-345, 2012.
66. M. Mazagova, H. Buikema, A. van Buiten, et al., "Genetic deletion of growth differentiation factor 15 augments renal damage in both type 1 and type 2 models of diabetes," The American Journal of Physiology-Renal Physiology, vol. 305, no. 9, pp. F1249-F1264, 2013.
67. H. Kolb and T. Mandrup-Poulsen, "An immune origin of type 2 diabetes?" Diabetologia, vol. 48, no. 6, pp. 1038-1050, 2005.
68. J. A. Ehses, A. Perren, E. Eppler, et al., "Increased number of islet-associated macrophages in type 2 diabetes," Diabetes, vol. 56, no. 9, pp. 2356-2370, 2007.
69. WorldHealthOrganization, World Health Statistics 2012, World Health Organization, Geneva, Switzerland, 2012.
70. T. Ago and J. Sadoshima, "GDF15, a cardioprotective TGF-beta superfamily protein," Circulation Research, vol. 98, no. 3, pp. 294-297, 2006.
71. J. Xu, T. R. Kimball, J. N. Lorenz, et al., "GDF15/MIC-1 functions as a protective and anti hypertrophic factor released from the myocardium in association with SMAD protein activation," Circulation Research, vol. 98, no. 3, pp. 342-350, 2006.
72. K. M. Eggers, T. Kempf, B. Lagerqvist, et al., "Growthdifferentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome," Circulation: Cardiovascular Genetics, vol. 3, no. 1, pp. 89-96, 2010.
73. L. Lind, L. Wallentin, T. Kempf, et al., "Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study," European Heart Journal, vol. 30, no. 19, pp. 2346-2353, 2009.
74. C. Cuspidi, C. Sala, F. Negri, G. Mancia, and A. Morganti, "Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies," Journal of Human Hypertension, vol. 26, no. 6, pp. 343-349, 2012.
75. A. V. Chobanian, G. L. Bakris, H. R. Black, et al., "The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report," Journal of the American Medical Association, vol. 289, no. 19, pp. 2560-2572, 2003.
76. S. Zhan, M. Liu, W. Yao, et al., "Prevalence and relevant factors on echocardiographic left ventricular hypertrophy among community-based hypertensive patients in Shanghai," Zhonghua Liu Xing Bing Xue Za Zhi, vol. 23, no. 3, pp. 182-185, 2002.
77. D. Levy, R. J. Garrison, D. D. Savage, W. B. Kannel, and W. P. Castelli, "Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study," The New England Journal of Medicine, vol. 322, no. 22, pp. 1561-1566, 1990.
78. G. Schillaci, P. Verdecchia, C. Porcellati, O. Cuccurullo, C. Cosco, and F. Perticone, "Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension," Hypertension, vol. 35, no. 2, pp. 580-586, 2000.
79. X. Y. Xu, Y. Nie, F. F. Wang, et al., "Growth differentiation factor (GDF)-15 blocks norepinephrine induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation,"The Journal of Biological Chemistry, vol. 289, no. 14, pp. 10084-10094, 2014.
80. S. Hanatani, Y. Izumiya, S. Takashio, et al., "Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts," Heart and Vessels, vol. 29, no. 2, pp. 231-237, 2014.
81. O. F. Bueno and J. D. Molkentin, "Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death," Circulation Research, vol. 91, no. 9, pp. 776-781, 2002.
82. R. Derynck and Y. E. Zhang, "Smad-dependent and Smadindependent pathways in TGF-beta family signalling," Nature, vol. 425, no. 6958, pp. 577-584, 2003.
83. J. Heger, E. Schiegnitz, D. Von Waldthausen, M. M. Anwar, H. M. Piper, and G. Euler, "Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes," Journal of Cellular Physiology, vol. 224, no. 1, pp. 120-126, 2010.
84. R. Stahrenberg, F. Edelmann, M. Mende, et al., "The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction," European Journal of Heart Failure, vol. 12, no. 12, pp. 1309-1316, 2010.
85. B. Chen, D. Lu, Y. Fu, et al., "Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53," British Journal of Pharmacology, vol. 171, no. 15, pp. 3741-3753, 2014.
86. D. Frank, C. Kuhn, B. Brors, et al., "Gene expression pattern in biomechanically stretched cardiomyocytes: evidence for a stretch-specific gene program," Hypertension, vol. 51, no. 2, pp. 309-318, 2008.
87. G. A. Bonaterra, S. Zügel, J. Thogersen, et al., "Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6-dependent inflammatory response to vascular injury," Journal of the American Heart Association, vol. 1, no. 6, Article ID e002550, 2012.
88. S. Lamouille, C. Mallet, J.-J. Felge, and S. Bailly, "Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis," Blood, vol. 100, no. 13, pp. 4495-4501, 2002.
89. P. Secchiero, F. Corallini, A. Gonelli, et al., "Antiangiogenic activity of theMDM2 antagonist nutlin-3," Circulation Research, vol. 100, no. 1, pp. 61-69, 2007.
90. S. J. Huh, C. Y. Chung, A. Sharma, and G. P. Robertson, "Macrophage inhibitory cytokine-1 regulates melanoma vascular development," The American Journal of Pathology, vol. 176, no. 6, pp. 2948-2957, 2010.
91. J. N. Topper, "TGF-beta in the cardiovascular system:Molecular mechanisms of a context-specific growth factor," Trends in Cardiovascular Medicine, vol. 10, no. 3, pp. 132-137, 2000.
92. S. Czernichow and S. Hercberg, "Interventional studies concerning the role of antioxidant vitamins in cardiovascular diseases: a review,"The Journal of Nutrition, Health&Aging, vol. 5, no. 3, pp. 188-195, 2001.
93. H. Tashiro, H. Shimokawa, K. Yamamoto, M. Momohara, H. Tada, and A. Takeshita, "Altered plasma levels of cytokines in patients with ischemic heart disease," Coronary Artery Disease, vol. 8, no. 3-4, pp. 143-147, 1997.
94. A. Bobik, A. Agrotis, P. Kanellakis, et al., "Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions: colocalization implicates TGF-beta in fibrofatty lesion development," Circulation, vol. 99, no. 22, pp. 2883-2891, 1999.
95. R. Hutter, C. Valdiviezo, B. V. Sauter, et al., "Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis," Circulation, vol. 109, no. 16, pp. 2001-2008, 2004.
96. E. S. Wintergerst, J. Jelk, C. Rahner, and R. Asmis, "Apoptosis induced by oxidized low density lipoprotein in human monocyte-derived macrophages involves CD36 and activation of caspase-3," European Journal of Biochemistry, vol. 267, no. 19, pp. 6050-6059, 2000.
97. R. Kinscherf, H.-P. Deigner, C. Usinger, et al., "Induction of mitochondrial manganese superoxide dismutase in macrophages by oxidized LDL-its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits," The FASEB Journal, vol. 11, no. 14, pp. 1317-1328, 1997.
98. R. Kinscherf, R. Claus, M. Wagner, et al., "Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent," FASEB Journal, vol. 12, no. 6, pp. 461-467, 1998.
99. C. Ihling, G. Menzel, E. Wellens, J. S. Monting, H. E. Schaefer, and A. M. Zeiher, "Topographical association between the cyclin-dependent kinases inhibitor P21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 10, pp. 2218-2224, 1997.
100. Z. Mallat, J. Ohan, G. Lesèche, and A. Tedgui, "Colocalization of CPP-32 with apoptotic cells in human atherosclerotic plaques," Circulation, vol. 96, no. 2, pp. 424-428, 1997.
101. S. Jovinge, M. P. S. Ares, B. Kallin, and J. Nilsson, "Human monocytes/macrophages release TNF-alpha in response to Ox-LDL," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 16, no. 12, pp. 1573-1579, 1997.
102. R. Kinscherf, R. Claus, H. P. Deigner, et al., "Modified low density lipoprotein delivers substrate for ceramide formation and stimulates the sphingomyelin-ceramide pathway in human macrophages," FEBS Letters, vol. 405, no. 1, pp. 55-59, 1997.
103. R. Kinscherf, M. Wagner, H. Kamencic, et al., "Characterization of apoptotic macrophages in atheromatous tissue of humans and heritable hyperlipidemic rabbits," Atherosclerosis, vol. 144, no. 1, pp. 33-39, 1999.
104. S. C. A. De Jager, B. Bermúdez, I. Bot, et al., "Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis," Journal of Experimental Medicine, vol. 208, no. 2, pp. 217-225, 2011.
105. T. Kempf and K. C. Wollert, "Growth differentiation factor-15: a new biomarker in cardiovascular disease," Herz, vol. 34, no. 8, pp. 594-599, 2009.
106. S. Allender, P. Scarborough, M. OFlaherty, and S. Capewell, "Patterns of coronary heart disease mortality over the 20th century in England and Wales: possible plateaus in the rate of decline," BMC Public Health, vol. 8, article 148, 2008.
107. T. Kempf, A. Zarbock, C. Widera, et al., "GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice," Nature Medicine, vol. 17, no. 5, pp. 581-588, 2011.
108. J. Berkman and H. Rifkin, "Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel Wilson): report of a case," Metabolism: Clinical and Experimental, vol. 22, no. 5, pp. 715-722, 1973.
109. R. P. E. van Dokkum, W. B. A. Eijkelkamp, A. C. A. Kluppel et al., "Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction," Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3103-3110, 2004.
110. A. S. Desai, R. Toto, P. Jarolim, et al., "Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD," American Journal of Kidney Diseases, vol. 58, no. 5, pp. 717-728, 2011.
111. J. E. Ho, S. J. Hwang, K. C. Wollert, et al., "Biomarkers of cardiovascular stress and incident chronic kidney disease," Clinical Chemistry, vol. 59, no. 11, pp. 1613-1620, 2013.
112. T. A. Zimmers, X. Jin, E. C. Hsiao, S. A. McGrath, A. F. Esquela, and L. G. Koniaris, "Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury," Shock, vol. 23, no. 6, pp. 543-548, 2005.
113. J. P. D. van Huyen, L. Cheval, M. Bloch-Faure, et al., "GDF15 triggers homeostatic proliferation of acid-secreting collecting duct cells," Journal of the American Society of Nephrology, vol. 19, no. 10, pp. 1965-1974, 2008.
114. M. S. Simonson, M. Tiktin, S. M. Debanne, et al., "Therenal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: a pilot study," The American Journal of Physiology-Renal Physiology, vol. 302, no. 7, pp. F820-F829, 2012.
115. A. D. Hingorani, J. Cross, R. K. Kharbanda, et al., "Acute systemic inflammation impairs endothelium-dependent dilatation in humans," Circulation, vol. 102, no. 9, pp. 994-999, 2000.
116. T. Kempf, S. von Haehling, T. Peter, et al., "Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure," Journal of the American College of Cardiology, vol. 50, no. 11, pp. 1054-1060, 2007.
117. A. Clerk, T. J. Kemp, G. Zoumpoulidou, and P. H. Sugden, "Cardiac myocyte gene expression profiling during H2O2-induced apoptosis," Physiological Genomics, vol. 29, no. 2, pp. 118-127, 2007.
118. E.-S. Han, F. L. Muller, V. I. Pérez, et al., "The in vivo gene expression signature of oxidative stress," Physiological Genomics, vol. 34, no. 1, pp. 112-126, 2008.
119. M. Zhang, S. Lu, X. Wu, et al., "Multimarker approach for the prediction of cardiovascular events in patients with mild to moderate coronary artery lesions a 3-year follow-up study," International Heart Journal, vol. 53, no. 2, pp. 85-90, 2012.
120. R. B. Schnabel, A. Schulz, C. M. Messowet al., "Multiplemarker approach to risk stratification in patients with stable coronary artery disease," EuropeanHeart Journal, vol. 31, no. 24, pp. 3024-3031, 2010.